Distinct differences in LC3+ EVs levels were observed in TB mouse models before and after immunotherapy, and the expression levels of LC3+ EVs for benign breast disease and breast cancer were clearly distinguished. Here, MAP1LC3A is linked to breast fibrocystic disease.